Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: therapeutic agents - HanAll Biopharma

Next Previous
X
Search
Drug Profile

Research programme: therapeutic agents - HanAll Biopharma

Alternative Names: HL 152B; HL 156Can; HL 176; HL004; HL010; HL011; HL020; HL021; HL022; HL023; HL024; HL025; HL026; HL027; HL030; HL034 (oral TPO agent) - HanAll; HL038; HL039; HL051; HL076; HL102; HL130; HL156; HL157 (oral monoclonal antibody) - HanAll Biopharma; HL160; HL177; HL178-TXNIP; HL178-TXNIP (negative regulator); metformin butyrate - HanAll BioPharma; Second-generation metformin products - HanAll Biopharma

Latest Information Update: 06 Oct 2015

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanAll Biopharma; Korea Research Institute of Chemical Technology
  • Developer HanAll Biopharma
  • Class Monoclonal antibodies; Proteins; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Cell adhesion molecule inhibitors; Gluconeogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Angina pectoris; Asthma; Atherosclerosis; Atopic dermatitis; Cancer; Diabetes mellitus; Hypertension; Inborn genetic disorders; Obesity; Parkinson's disease; Thrombocytopenia

Most Recent Events

  • 01 Dec 2014 HanAll in-licenses OmniRat®, OmniMouse® and OmniFlic® technology from Open Monoclonal Technology
  • 24 Aug 2012 Preclinical trials in Age-related macular degeneration in South Korea (Ophthalmic)
  • 24 Aug 2012 Preclinical trials in Autoimmune disorders in South Korea (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top